Here are the S-3 shelf registrations from Picard Medical, Inc. (PMI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMI filings page.
Picard Medical, Inc. (PMI) is registering for resale by selling stockholders up to 500,000 shares of Common Stock: 250,000 issuable on conversion of unsecured notes and 250,000 on exercise of related pre-funded warrants. The table includes selling stockholders Fengjun Xue (200,000 shares) and Xiangdie Liu (150,000 shares). Resales may occur only after the registration statement becomes effective. PMI receives no proceeds from resales, but receives $0.0001 per warrant share exercised.
The notes have $1.0 million aggregate principal, bear 3.0% annual interest and mature September 30, 2027. The conversion price is the higher of $4.00 per share and the prior trading day’s closing price; each converted share also results in a warrant for one share at $0.0001, exercisable 60 days after issuance and expiring two years after issuance. The 4.99% beneficial-ownership limit may be raised at a holder’s option to 9.99% with 61 days’ prior notice; a 19.99% aggregate issuance cap, measured against shares outstanding on the issuance date, applies until stockholder approval. Shares outstanding were 2,458,574 as of October 13, 2026. NYSE American accepted PMI’s compliance plan, subject to quarterly review and milestones to regain compliance by November 8, 2027; the 2025 audit report includes a going-concern explanatory paragraph.
Picard Medical, Inc. (PMI) registered up to 500,000 common shares for resale by selling stockholders: 250,000 issuable upon conversion of its September 30, 2026 notes and 250,000 upon exercise of warrants issued upon conversion. Sales under the prospectus may begin only after the registration statement becomes effective; holders may sell all, some or none.
The notes have $1.0 million aggregate principal, bear 3.0% annual interest and mature September 30, 2027. Their conversion price is the higher of $4.00 per share or the closing price on the trading day immediately before conversion notice; the 250,000-share note conversion maximum excludes accrued interest. Warrants have a $0.0001 exercise price, are exercisable 60 days after issuance and expire on their second anniversary. PMI receives no proceeds from resales, but receives $0.0001 per share upon warrant exercise. NYSE American accepted PMI's compliance plan, subject to quarterly review and regaining compliance by November 8, 2027. The incorporated 2025 financial statements include an auditor's explanatory paragraph regarding PMI's ability to continue as a going concern.